BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 28801026)

  • 1. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
    Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM; Eyre S; Loughlin KR
    Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP; Greenberg RE; Steinberg GD
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
    Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
    Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
    Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
    J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
    Steinberg RL; Thomas LJ; Nepple KG
    Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
    Robins DJ; Sui W; Matulay JT; Ghandour R; Anderson CB; DeCastro GJ; McKiernan JM
    Urology; 2017 May; 103():149-153. PubMed ID: 28163086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.
    Liem EIML; Baard J; Cauberg ECC; Bus MTJ; de Bruin DM; Laguna Pes MP; de la Rosette JJMCH; de Reijke TM
    Med Oncol; 2017 Sep; 34(10):172. PubMed ID: 28866819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
    Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
    J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder.
    Watanabe E; Matsuyama H; Matsuda K; Ohmi C; Tei Y; Yoshihiro S; Ohmoto Y; Naito K
    Cancer Immunol Immunother; 2003 Aug; 52(8):481-6. PubMed ID: 12707736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.
    Nishiyama N; Kitamura H; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Masumori N
    Jpn J Clin Oncol; 2014 Nov; 44(11):1101-8. PubMed ID: 25139163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.
    Packiam VT; Johnson SC; Steinberg GD
    Cancer; 2017 Feb; 123(3):390-400. PubMed ID: 28112819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.